LONGEST FOLLOW-UP OF SURVIVAL AFTER TREATMENT WITH NIVOLUMAB REPORTED AT AACR ANNUAL MEETING 2016
Sunday, April 17, 2016 - 14:00
in Health & Medicine
A team of researchers led by Ludwig Cancer Research scientist Stephen Hodi reported today the results of the longest follow-up survival study conducted to date on patients with advanced melanoma who were treated with the PD-1 inhibitor nivolumab. Hodi and his colleagues announced at a press event during the American Association for Cancer Research Annual Meeting in New Orleans that 34 percent of the patients treated with this immunotherapy alone in a previous Phase 1 trial were still alive five years later.